Bevacizumab in advanced endometrial cancer
Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Rubinstein, Maria M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes - Gibson, Diane M. ELSEVIER, 2017, an international journal : official publication of the Society of Gynecologic Oncologists [u.a.], Orlando, Fla |
|---|---|
| Übergeordnetes Werk: |
volume:161 ; year:2021 ; number:3 ; pages:720-726 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ygyno.2021.04.016 |
|---|
| Katalog-ID: |
ELV054143934 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV054143934 | ||
| 003 | DE-627 | ||
| 005 | 20230624204829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ygyno.2021.04.016 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001889.pica |
| 035 | |a (DE-627)ELV054143934 | ||
| 035 | |a (ELSEVIER)S0090-8258(21)00326-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.11 |2 bkl | ||
| 100 | 1 | |a Rubinstein, Maria M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bevacizumab in advanced endometrial cancer |
| 264 | 1 | |c 2021 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer. | ||
| 700 | 1 | |a Dickinson, Shannan |4 oth | |
| 700 | 1 | |a Narayan, Priyanka |4 oth | |
| 700 | 1 | |a Zhou, Qin |4 oth | |
| 700 | 1 | |a Iasonos, Alexia |4 oth | |
| 700 | 1 | |a Ma, Weining |4 oth | |
| 700 | 1 | |a Lakhman, Yulia |4 oth | |
| 700 | 1 | |a Makker, Vicky |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Academic Press |a Gibson, Diane M. ELSEVIER |t Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |d 2017 |d an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] |g Orlando, Fla |w (DE-627)ELV000708127 |
| 773 | 1 | 8 | |g volume:161 |g year:2021 |g number:3 |g pages:720-726 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ygyno.2021.04.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.11 |j Präventivmedizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 161 |j 2021 |e 3 |h 720-726 |g 7 | ||
| author_variant |
m m r mm mmr |
|---|---|
| matchkey_str |
rubinsteinmariamdickinsonshannannarayanp:2021----:eaiuaiavneedm |
| hierarchy_sort_str |
2021 |
| bklnumber |
44.11 |
| publishDate |
2021 |
| allfields |
10.1016/j.ygyno.2021.04.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001889.pica (DE-627)ELV054143934 (ELSEVIER)S0090-8258(21)00326-7 DE-627 ger DE-627 rakwb eng 610 VZ 44.11 bkl Rubinstein, Maria M. verfasserin aut Bevacizumab in advanced endometrial cancer 2021 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer. Dickinson, Shannan oth Narayan, Priyanka oth Zhou, Qin oth Iasonos, Alexia oth Ma, Weining oth Lakhman, Yulia oth Makker, Vicky oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:161 year:2021 number:3 pages:720-726 extent:7 https://doi.org/10.1016/j.ygyno.2021.04.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 161 2021 3 720-726 7 |
| spelling |
10.1016/j.ygyno.2021.04.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001889.pica (DE-627)ELV054143934 (ELSEVIER)S0090-8258(21)00326-7 DE-627 ger DE-627 rakwb eng 610 VZ 44.11 bkl Rubinstein, Maria M. verfasserin aut Bevacizumab in advanced endometrial cancer 2021 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer. Dickinson, Shannan oth Narayan, Priyanka oth Zhou, Qin oth Iasonos, Alexia oth Ma, Weining oth Lakhman, Yulia oth Makker, Vicky oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:161 year:2021 number:3 pages:720-726 extent:7 https://doi.org/10.1016/j.ygyno.2021.04.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 161 2021 3 720-726 7 |
| allfields_unstemmed |
10.1016/j.ygyno.2021.04.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001889.pica (DE-627)ELV054143934 (ELSEVIER)S0090-8258(21)00326-7 DE-627 ger DE-627 rakwb eng 610 VZ 44.11 bkl Rubinstein, Maria M. verfasserin aut Bevacizumab in advanced endometrial cancer 2021 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer. Dickinson, Shannan oth Narayan, Priyanka oth Zhou, Qin oth Iasonos, Alexia oth Ma, Weining oth Lakhman, Yulia oth Makker, Vicky oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:161 year:2021 number:3 pages:720-726 extent:7 https://doi.org/10.1016/j.ygyno.2021.04.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 161 2021 3 720-726 7 |
| allfieldsGer |
10.1016/j.ygyno.2021.04.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001889.pica (DE-627)ELV054143934 (ELSEVIER)S0090-8258(21)00326-7 DE-627 ger DE-627 rakwb eng 610 VZ 44.11 bkl Rubinstein, Maria M. verfasserin aut Bevacizumab in advanced endometrial cancer 2021 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer. Dickinson, Shannan oth Narayan, Priyanka oth Zhou, Qin oth Iasonos, Alexia oth Ma, Weining oth Lakhman, Yulia oth Makker, Vicky oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:161 year:2021 number:3 pages:720-726 extent:7 https://doi.org/10.1016/j.ygyno.2021.04.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 161 2021 3 720-726 7 |
| allfieldsSound |
10.1016/j.ygyno.2021.04.016 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001889.pica (DE-627)ELV054143934 (ELSEVIER)S0090-8258(21)00326-7 DE-627 ger DE-627 rakwb eng 610 VZ 44.11 bkl Rubinstein, Maria M. verfasserin aut Bevacizumab in advanced endometrial cancer 2021 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer. Dickinson, Shannan oth Narayan, Priyanka oth Zhou, Qin oth Iasonos, Alexia oth Ma, Weining oth Lakhman, Yulia oth Makker, Vicky oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:161 year:2021 number:3 pages:720-726 extent:7 https://doi.org/10.1016/j.ygyno.2021.04.016 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 161 2021 3 720-726 7 |
| language |
English |
| source |
Enthalten in Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes Orlando, Fla volume:161 year:2021 number:3 pages:720-726 extent:7 |
| sourceStr |
Enthalten in Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes Orlando, Fla volume:161 year:2021 number:3 pages:720-726 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Präventivmedizin |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| authorswithroles_txt_mv |
Rubinstein, Maria M. @@aut@@ Dickinson, Shannan @@oth@@ Narayan, Priyanka @@oth@@ Zhou, Qin @@oth@@ Iasonos, Alexia @@oth@@ Ma, Weining @@oth@@ Lakhman, Yulia @@oth@@ Makker, Vicky @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000708127 |
| dewey-sort |
3610 |
| id |
ELV054143934 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV054143934</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624204829.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ygyno.2021.04.016</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001889.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV054143934</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0090-8258(21)00326-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.11</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rubinstein, Maria M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bevacizumab in advanced endometrial cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dickinson, Shannan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Narayan, Priyanka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Qin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Iasonos, Alexia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ma, Weining</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lakhman, Yulia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Makker, Vicky</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Gibson, Diane M. ELSEVIER</subfield><subfield code="t">Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes</subfield><subfield code="d">2017</subfield><subfield code="d">an international journal : official publication of the Society of Gynecologic Oncologists [u.a.]</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV000708127</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:161</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:720-726</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ygyno.2021.04.016</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.11</subfield><subfield code="j">Präventivmedizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">161</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield><subfield code="h">720-726</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| author |
Rubinstein, Maria M. |
| spellingShingle |
Rubinstein, Maria M. ddc 610 bkl 44.11 Bevacizumab in advanced endometrial cancer |
| authorStr |
Rubinstein, Maria M. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000708127 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.11 bkl Bevacizumab in advanced endometrial cancer |
| topic |
ddc 610 bkl 44.11 |
| topic_unstemmed |
ddc 610 bkl 44.11 |
| topic_browse |
ddc 610 bkl 44.11 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s d sd p n pn q z qz a i ai w m wm y l yl v m vm |
| hierarchy_parent_title |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| hierarchy_parent_id |
ELV000708127 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000708127 |
| title |
Bevacizumab in advanced endometrial cancer |
| ctrlnum |
(DE-627)ELV054143934 (ELSEVIER)S0090-8258(21)00326-7 |
| title_full |
Bevacizumab in advanced endometrial cancer |
| author_sort |
Rubinstein, Maria M. |
| journal |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| journalStr |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
720 |
| author_browse |
Rubinstein, Maria M. |
| container_volume |
161 |
| physical |
7 |
| class |
610 VZ 44.11 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Rubinstein, Maria M. |
| doi_str_mv |
10.1016/j.ygyno.2021.04.016 |
| dewey-full |
610 |
| title_sort |
bevacizumab in advanced endometrial cancer |
| title_auth |
Bevacizumab in advanced endometrial cancer |
| abstract |
Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer. |
| abstractGer |
Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer. |
| abstract_unstemmed |
Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
3 |
| title_short |
Bevacizumab in advanced endometrial cancer |
| url |
https://doi.org/10.1016/j.ygyno.2021.04.016 |
| remote_bool |
true |
| author2 |
Dickinson, Shannan Narayan, Priyanka Zhou, Qin Iasonos, Alexia Ma, Weining Lakhman, Yulia Makker, Vicky |
| author2Str |
Dickinson, Shannan Narayan, Priyanka Zhou, Qin Iasonos, Alexia Ma, Weining Lakhman, Yulia Makker, Vicky |
| ppnlink |
ELV000708127 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ygyno.2021.04.016 |
| up_date |
2024-07-06T20:54:24.222Z |
| _version_ |
1803864521280847872 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV054143934</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624204829.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ygyno.2021.04.016</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001889.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV054143934</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0090-8258(21)00326-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.11</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rubinstein, Maria M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bevacizumab in advanced endometrial cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dickinson, Shannan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Narayan, Priyanka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Qin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Iasonos, Alexia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ma, Weining</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lakhman, Yulia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Makker, Vicky</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Gibson, Diane M. ELSEVIER</subfield><subfield code="t">Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes</subfield><subfield code="d">2017</subfield><subfield code="d">an international journal : official publication of the Society of Gynecologic Oncologists [u.a.]</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV000708127</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:161</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:720-726</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ygyno.2021.04.016</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.11</subfield><subfield code="j">Präventivmedizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">161</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield><subfield code="h">720-726</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| score |
7.399976 |